Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cellectis SA ( (CLLS) ) just unveiled an update.
Cellectis S.A., a clinical-stage biotechnology company specializing in off-the-shelf gene-edited CAR T-cell therapies and broader cell and gene therapy platforms, maintains full control of its value chain through in-house manufacturing and operates from hubs in France and the United States. The company, dual-listed on Nasdaq and Euronext Growth, targets oncology and other therapeutic areas with its allogeneic approach.
On May 4, 2026, Cellectis announced it will report its financial results for the first quarter of 2026, covering the period ended March 31, 2026, after the close of the U.S. market on May 11, 2026. The announcement signals an upcoming update for investors via a press release on the company’s website, although Cellectis will not host a conference call, directing stakeholders instead to its investor relations team for any follow-up questions.
The most recent analyst rating on (CLLS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
The score is held back primarily by weak financial performance—persistent losses, renewed 2025 cash burn, and rising leverage—partly offset by a relatively constructive technical setup with the stock trading above several key moving averages. Valuation is constrained by negative earnings and the absence of a dividend.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a clinical-stage biotechnology company focused on developing cell and gene therapies using a proprietary gene-editing platform. It emphasizes an allogeneic, off-the-shelf approach to CAR T immunotherapies for oncology and is also building gene therapies for other indications, supported by in-house manufacturing and operations in Paris, New York and Raleigh.
Average Trading Volume: 41,831
Technical Sentiment Signal: Buy
Current Market Cap: $282M
Learn more about CLLS stock on TipRanks’ Stock Analysis page.